標(biāo)題: Titlebook: Biopharma in China; Innovation, Trends a Sven Agten,Ben Wu Book 2024 The Author(s), under exclusive license to Springer Nature Singapore Pt [打印本頁] 作者: coherent 時(shí)間: 2025-3-21 17:40
書目名稱Biopharma in China影響因子(影響力)
書目名稱Biopharma in China影響因子(影響力)學(xué)科排名
書目名稱Biopharma in China網(wǎng)絡(luò)公開度
書目名稱Biopharma in China網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biopharma in China被引頻次
書目名稱Biopharma in China被引頻次學(xué)科排名
書目名稱Biopharma in China年度引用
書目名稱Biopharma in China年度引用學(xué)科排名
書目名稱Biopharma in China讀者反饋
書目名稱Biopharma in China讀者反饋學(xué)科排名
作者: 物質(zhì) 時(shí)間: 2025-3-21 22:18 作者: 否決 時(shí)間: 2025-3-22 01:04 作者: 傻 時(shí)間: 2025-3-22 08:09
Innovation in the Chinese Biopharma Sector: From Me-too to First-in-Class,decade old, but a momentous shift has occurred already. By now China’s R&D has come a long way, moving away from generic drugs to the latest technologies. Starting in the early 2000s, a first wave of new generation innovative pharma companies formed in China. As scientific research and core R&D howe作者: Reservation 時(shí)間: 2025-3-22 09:06
The Art of the Biopharma Deal: The China Angle,tors. Anybody who wants to raise money from Chinese investors or strike a partnering or cooperation deal with Chinese companies however, needs to understand what investors or Chinese pharma companies are looking for. And because of the vast differences and needs of the Chinese healthcare and pharmac作者: inchoate 時(shí)間: 2025-3-22 14:00
End of the First Cycle, 2022 and Beyond: A Drastic Reset, Increased Challenges But Also New Opportutween the period 2018–2022 we witnessed a growth phase, catalyzed by even more funding and new IPO channels in Hong Kong and Shanghai. 2022 saw the start of a reset phase characterized by a drastic market correction, in line with global biotech trends. Companies and healthcare funds alike need to re作者: infantile 時(shí)間: 2025-3-22 17:34 作者: 游行 時(shí)間: 2025-3-23 00:48
Springer Series in Optical Sciencesvation was non-existent. The ‘Healthy China 2030’ initiative however, changed all that. Over the last decade China has made significant strides in upgrading and updating all aspects of the healthcare system. A key pillar in these upgrades were the changes being made in its legal and regulatory frame作者: 外來 時(shí)間: 2025-3-23 01:41
https://doi.org/10.1007/978-3-540-38950-7ive domestic growth in the pharma and biotech space. With the largest population in the world and with little access to the latest innovative medicines, China provided huge market opportunities. Regulatory reforms made approval of new drugs much easier, which led to venture capitalists eying the Chi作者: 憲法沒有 時(shí)間: 2025-3-23 06:56 作者: eucalyptus 時(shí)間: 2025-3-23 09:47 作者: fleeting 時(shí)間: 2025-3-23 16:30 作者: 過濾 時(shí)間: 2025-3-23 19:13
Sven Agten,Ben WuExplores legal issues around medicine in China.Examines the growing biopharma industry in China.Offers insights for professionals作者: Paleontology 時(shí)間: 2025-3-24 00:15 作者: Intersect 時(shí)間: 2025-3-24 06:04 作者: senile-dementia 時(shí)間: 2025-3-24 08:03 作者: 抵押貸款 時(shí)間: 2025-3-24 12:44 作者: 在前面 時(shí)間: 2025-3-24 18:28 作者: 誘導(dǎo) 時(shí)間: 2025-3-24 21:00 作者: B-cell 時(shí)間: 2025-3-25 02:29
Innovation in the Chinese Biopharma Sector: From Me-too to First-in-Class,eld of antibodies. Learning from past experiences and urged on by their investors, since 2020 an increasing number of Chinese biopharmas have embarked on a strategy to develop first-in-class drugs with global potential using novel technologies. Especially during the pandemic, China became host to a 作者: Scintigraphy 時(shí)間: 2025-3-25 06:17 作者: 發(fā)出眩目光芒 時(shí)間: 2025-3-25 10:03 作者: Lignans 時(shí)間: 2025-3-25 14:47 作者: 替代品 時(shí)間: 2025-3-25 18:21 作者: 單獨(dú) 時(shí)間: 2025-3-25 20:02 作者: Chronic 時(shí)間: 2025-3-26 01:38
https://doi.org/10.1007/978-3-540-38950-7eld of antibodies. Learning from past experiences and urged on by their investors, since 2020 an increasing number of Chinese biopharmas have embarked on a strategy to develop first-in-class drugs with global potential using novel technologies. Especially during the pandemic, China became host to a 作者: 赤字 時(shí)間: 2025-3-26 04:52
Springer Series in Optical Sciencesd, venture capital backed biopharma companies, and the traditional Chinese pharmaceutical companies. It’s important to understand the background of these companies. The traditional pharma companies are not rooted in innovation, and as such are not always that familiar with the process of drug discov作者: deficiency 時(shí)間: 2025-3-26 08:40 作者: 死貓他燒焦 時(shí)間: 2025-3-26 15:57
le, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn’t, and how as a foreign company can tap into the world’s second largest healthcare market..978-981-97-1471-1作者: Vulvodynia 時(shí)間: 2025-3-26 20:03
Book 2024pectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has b作者: ROOF 時(shí)間: 2025-3-26 22:45 作者: Heresy 時(shí)間: 2025-3-27 04:03 作者: 失望昨天 時(shí)間: 2025-3-27 06:49
10樓作者: strain 時(shí)間: 2025-3-27 11:42
10樓作者: 你不公正 時(shí)間: 2025-3-27 16:47
10樓作者: 陰謀 時(shí)間: 2025-3-27 19:57
10樓
